Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
“What can I eliminate from my diet to cure my arthritis?” is the question every client with arthritis asks me. Numerous case reports document patients who achieved lower markers of inflammation and reduced pain and stiffness associated with the removal of one or two food groups from a diet, but historically, no compelling evidence has…
Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…
How can we best care for our patients from a joint & cardiovascular perspective? That’s the question Christina Charles-Schoeman, MD, MS, professor of medicine and chief, Division of Rheumatology, University of California Los Angeles Medical Center, Santa Monica, Calif., addressed in a session at ACR Convergence 2024.
Many rheumatologists may not be trained to properly identify the signs of skin disease in patients with dark skin, but in this ACR Convergence session, experts provide practical guidance for diagnosis.
In this case report, a patient with voriconazole-induced periostitis exhibits classic symptoms & elevated ALP levels, which quickly resolve following the discontinuation of voriconazole.
Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.